|
| Press Releases |
|
 |
|
| Tuesday, August 13, 2013 |
|
|
New Strategy to Disarm the Dengue Virus Brings New Hope for a Universal Dengue Vaccine |
| A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network (SIgN). more info >> |
|
| Tuesday, August 6, 2013 |
|
|
Unexpected Synergy Between Two Cancer-linked Proteins Offers Hope for Personalised Cancer Therapy |
| A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology (IMCB) have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. more info >> |
|
| Saturday, July 27, 2013 |
|
|
Singapore Scientists Discover New Drug Targets for Aggressive Breast Cancer |
Scientists at A*STAR's Genome Institute of Singapore (GIS) led in a study that has identified genes that are potential targets for therapeutic drugs against aggressive breast cancer. These findings were reported in the July 2013 issue of PNAS.
more info >> |
|
| Tuesday, July 2, 2013 |
|
|
Genome Institute of Singapore Scientists Discover Molecular Communication Network in Human Stem Cells |
| Scientists at A*STAR's Genome Institute of Singapore (GIS) and the Max Planck Institute for Molecular Genetics (MPIMG) in Berlin (Germany) have discovered a molecular network in human embryonic stem cells (hESCs) that integrates cell communication signals to keep the cell in its stem cell state. These findings were reported in the June 2013 issue of Molecular Cell. more info >> |
|
| Friday, May 17, 2013 |
|
|
A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing |
| Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle (VLP) technology. more info >> |
|
| Thursday, April 25, 2013 |
|
|
A*STAR and Veredus Laboratories Create Market's First Lab-on-Chip for the Detection of Multiple Tropical Infectious Diseases |
| The Agency for Science, Technology and Research (A*STAR) and Veredus Laboratories, a leading supplier of innovative molecular diagnostic tools, announced the launch of VereTrop(TM), the first biochip in the molecular diagnostics market that can identify 13 different major tropical diseases from a single blood sample. more info >> |
|
| Monday, April 22, 2013 |
|
|
Understanding Abnormal Proteins in Degenerative Diseases |
| Now, a new class of ultrasmall peptides developed by the Institute of Bioengineering and Nanotechnology (IBN) offers scientists a platform for understanding abnormal proteins, providing them with the insights required to design more effective treatments for degenerative diseases such as Alzheimer's, diabetes and cancer. more info >> |
|
| Thursday, April 18, 2013 |
|
|
Singapore Scientist Wins Coveted Chen New Investigator Award 2013 |
| Dr Patrick Tan from A*STAR's Genome Institute of Singapore (GIS) has received the 2013 Chen New Investigator Award from the international Human Genome Organisation (HUGO). more info >> |
|
|
A*STAR Scientists Decipher Genome Code of a Living Fossil |
| An enigmatic prehistoric fish has brought scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) together with researchers from all over the world to crack its genomic code. Findings from the study are providing new insights into the evolutionary history of the African coelacanth and possible clues as to how aquatic creatures transitioned to life on land. more info >> |
|
| Friday, April 5, 2013 |
|
|
A*STAR Scientist Alex Matter Awarded Prestigious Szent-Gyorgyi Prize For Progress In Cancer Research |
| Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gyorgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
DK88 Casino Officially Launches in Malaysia
Feb 21, 2026 21:50 HKT/SGT
|
|
|
Graphene Manufacturing Group and Tickford Racing Unite to Push Performance Efficiency On and Off the Track
Feb 20, 2026 20:59 HKT/SGT
|
|
|
Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST
|
|
|
首程控股可轉債全額轉股落地 流動性釋放疊加獲利盤了結迎估值重塑
Feb 20, 2026 19:15 HKT/SGT
|
|
|
Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST
|
|
|
首程控股可转债全额转股落地 流动性释放叠加获利盘了结迎估值重塑
Feb 20, 2026 18:43 HKT/SGT
|
|
|
春晚科技秀背后的布局者：首程控股绑定三大龙头 筑牢机器人生态壁垒
Feb 20, 2026 18:24 HKT/SGT
|
|
|
Hong Kong designer labels shine at London Fashion Week
Feb 20, 2026 17:04 HKT/SGT
|
|
|
Spritzer EcoPark Champions Inclusive Experiences in Nature Through Meaningful Community Engagement
Feb 20, 2026 15:37 HKT/SGT
|
|
|
Shoucheng Holdings Draws Focus After Portfolio Companies Appear in Spring Festival Gala Robotics Showcase
Feb 20, 2026 15:29 HKT/SGT
|
|
|
春晚科技秀背後的佈局者：首程控股綁定三大龍頭 築牢機器人生態壁壘
Feb 20, 2026 14:19 HKT/SGT
|
|
|
首程控股（0697.HK）機器人版圖閃耀2026春晚：投資回報步入爆發期
Feb 20, 2026 13:24 HKT/SGT
|
|
|
被投企業登上國家級舞台 首程控股「資本+場景+產業鏈」邏輯獲得驗證 進入價值兌現階段
Feb 20, 2026 12:57 HKT/SGT
|
|
|
被投企业登上国家级舞台 首程控股"资本+场景+产业链"逻辑获得验证 进入价值兑现阶段
Feb 20, 2026 12:57 HKT/SGT
|
|
|
Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
